Compare Crispr Therapeutics AG (CRSP) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Lockheed Martin Corporation — how do they compare? Crispr Therapeutics AG trades at $51.11 (market cap $4.88B), while Lockheed Martin Corporation trades at $506.53 (market cap $117.22B). The key difference: Lockheed Martin Corporation is far larger — about 24× Crispr Therapeutics AG's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Lockheed Martin Corporation for 86 Days on average.
| CRSP | LMT | |
|---|---|---|
Market Cap | $4.88B | $117.22B |
Volume | 2,861,747 | 1,101,121 |
Sector | Health | Industrials |
52-Week High | $74.92 | $676.70 |
52-Week Low | $44.34 | $439.19 |
Typical Hold Time | 77 Days | 86 Days |
Enterprise Value | $3.30B | $133.96B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
Lockheed Martin (LMT) trades at $499.22, down 2.14% on the day, amid a bearish technical signal and recent earnings volatility. The company reported revenue growth to $75.05B in 2025, but net income margin declined to 6.68%. Analyst consensus remains bullish with a $635.33 price target, supported by strong defense spending trends and a 23-year dividend growth streak. Recent news highlights AI integration and F-35 program developments, though fixed-price contract risks persist.
LMT offers value with a P/E of 18.41 and robust cash flow, but faces execution risks from contract missteps and debt levels near 36% of assets. Upside hinges on defense budget continuity and operational efficiency, while margin pressure and competitive threats from peers like Boeing pose challenges. The stock's current discount to analyst targets presents a potential entry point for long-term investors, balanced by near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
